title: Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review.
abstract: Many men have coexistent erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). Phosphodiesterase type 5 (PDE5) inhibitors are effective for treating both of these conditions independently. In this review we summarise the evidence supporting a link between ED and LUTS/BPH, and the results from key clinical studies related to the use of PDE5 inhibitors for treating both conditions. The results from these studies suggest that men who have both ED and LUTS/BPH, and are concerned about their sexual dysfunction, might benefit from single-agent, holistic treatment with a PDE5 inhibitor.
authors.affiliation: Lilly Research Laboratories, Eli Lilly and Company, Dubai, United Arab Emirates.
authors.forename: Albert
authors.initials: A
authors.lastname: Haddad
authors.affiliation: Division of Urology, Saint Georges Hospital, Balamand University, Achrafieh, Beirut, Lebanon.
authors.forename: Michel
authors.initials: M
authors.lastname: Jabbour
authors.affiliation: Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
authors.forename: Muhammad
authors.initials: M
authors.lastname: Bulbul
keywords: 5ARI, 5α-reductase inhibitor; AE, adverse event; Benign prostatic hyperplasia; ED, erectile dysfunction; EF, erectile function (domain); Erectile dysfunction; IIEF, International Index of Erectile Function; LUTS; NO, nitric oxide; PDE5 inhibitor; PDE5, phosphodiesterase type 5; QoL, quality of life; ROCK, Rho-associated protein kinase; RhoA, Ras homologue gene family member A; cGMP, cyclic guanosine monophosphate